

**XII Riunione Annuale
Network Cochrane Italiano**



**LA TRASPARENZA NELLA
PRODUZIONE E DISSEMINAZIONE
DELLE INFORMAZIONI
SCIENTIFICHE**

PRIMA SESSIONE - **Chair:** *Giovanni Apolone*


La scelta e la prioritarizzazione dei quesiti della ricerca.

Prioritization of research topic

Lester Firkins

Silvio Garattini

RESEARCH: ARE WE ON TARGET?



LEVEL OF EVIDENCE/KNOWLEDGE

TABLE

Categorisation of treatment effects in *BMJ Clinical Evidence*



Beneficial

Interventions for which effectiveness has been demonstrated by clear evidence from RCTs, or the best alternative source of information, and for which expectation of harms is small compared with the benefits.



Likely to be beneficial

Interventions for which effectiveness is less well established than for those listed under 'beneficial'.



Trade off between benefits and harms

Interventions for which clinicians and patients should weigh up the beneficial and harmful effects according to individual circumstances and priorities.



Unknown effectiveness

Interventions for which there are currently insufficient data or data of inadequate quality.



Unlikely to be beneficial


Interventions for which lack of effectiveness is less well established than for those listed under 'likely to be ineffective or harmful'.



Likely to be ineffective or harmful

Interventions for which ineffectiveness or harmfulness has been demonstrated by clear evidence.

HOW MUCH WE DO NOT KNOW



FORTUNE

WHY WE'RE
LOSING
THE WAR ON
CANCER
[AND HOW TO WIN IT]

BY CLIFTON LEAF

COPYRIGHT © 2011 FORTUNE MEDIA, A DIVISION OF TIME INC.
You may make a single printed copy of this content, solely for your personal use.
For all other uses, including commercial and academic uses, please visit www.FortuneReprints.com and
www.FortunePermissions.com.

TRANSLATIONAL RESEARCH

Translation from
bench to bed

Translation into
clinical practice

Basic research

Clinical Research
Phase I, II and III

Clinical Practice

From Research To Practice

From Practice to Research


Clinical Research in the United States at a Crossroads

Proposal for a Novel Public-Private Partnership to Establish a National Clinical Research Enterprise

William F. Crowley, Jr. MD

JAMA, March 3, 2004—Vol 291, No. 9 (Reprinted)

©2004 American Medical Association. All rights reserved.



Clinical research can be viewed as encountering 2 separate roadblocks on the way toward improving public health. These 2 translational blocks have different factors creating each but whereas the National Institutes of Health has been consistently targeting the bench-to-bedside block, no one is taking responsibility for the second, which is integrally tied with the funding of the health care delivery system.